title: [Expression of p27 in rat kidney with unilateral ureteral obstruction and the therapeutic effect of enalapril].
abstract: OBJECTIVE
  To explore the effect of p27 in the renal tubule on the process of renal interstitial fibrosis caused by unilateral ureteral obstruction (UUO) in rats, and to examine the expression changes of p27 after enalapril intervention and to interpret the anti-fibrotic mechanism.
  
  
  METHODS
  Ninety rats were randomly divided into the sham-operated group (SOR), UUO group,and UUO+enalapril treatment group [enalapril: 10 mg/(kg.d)]. The rats of each group were respectively sacrificed on 7, 14, 21 days post-operatively. The renal pathological changes were dynamically observed by HE. The expression and dynamic changes of p27 were detected by immunohistochemistry. The level of p27 mRNA were detected by RT-PCR.
  
  
  RESULTS
  The expression of p27 in renal tubular epithelial cells and p27 mRNA were strongly positive in the SOR group. With degree of interstitial fibrosis aggravating, the expression of p27 mRNA was gradually reducing. Enalapril could improve the expression of p27 on the 14th and 21st days after the UUO.
  
  
  CONCLUSIONS
  (1) This study supports a causative role of p27 in the formation of fibrosis of renal mesenchyme in rats with UUO. (2) The anti-fibrotic mechanism of enalapril is partly the improvement of p27 expression.
authors.affiliation: Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Sun
authors.forename: Li-jian
authors.initials: LJ
authors.lastname: Tao
authors.forename: Ou
authors.initials: O
authors.lastname: Jin
authors.forename: Wang-bin
authors.initials: WB
authors.lastname: Ning
authors.forename: Tang
authors.initials: T
authors.lastname: Damu
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000096:biosynthesis* / Q000235:genetics; D004656:Enalapril / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D007684:Kidney Tubules / Q000378:metabolism; D009400:Nephrosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014517:Ureteral Obstruction / Q000150:complications
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D012333:RNA, Messenger; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004656:Enalapril